[S02DA03, antipyrine, Antipyrine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A14AA02, stanozolol, The therapeutic efficacy of Liothyronine can be increased when used in combination with Stanozolol.]
[J01GA01, streptomycin, Liothyronine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Liothyronine may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Liothyronine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Liothyronine.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Liothyronine.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Liothyronine.]
[M01AB02, sulindac, Sulindac may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Liothyronine.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Liothyronine.]
[M01AX04, apazone, Azapropazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01BB02, mercaptopurine, Liothyronine may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tamoxifen.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Liothyronine.]
[B01AE07, dabigatran etexilate, Liothyronine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Testosterone.]
[S03AA02, tetracycline, The excretion of Tetracycline can be decreased when combined with Liothyronine.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[R03DA07, theobromine, Liothyronine may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Liothyronine may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Liothyronine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Liothyronine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[G04BE06, moxisylyte, Liothyronine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[N05AL03, tiapride, Liothyronine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01ED01, timolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Timolol.]
[P01AB02, tinidazole, Liothyronine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, Liothyronine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Liothyronine.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Liothyronine.]
[M02AA21, tolmetin, Tolmetin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N06AX05, trazodone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Trazodone.]
[S01BA05, triamcinolone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Triamcinolone.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Liothyronine may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Liothyronine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, The excretion of Trifluridine can be decreased when combined with Liothyronine.]
[R03BA07, mometasone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Mometasone.]
[A03AA05, trimebutine, Liothyronine may decrease the excretion rate of Trimebutine which could result in a higher serum level.]
[J01EA01, trimethoprim, Liothyronine may decrease the excretion rate of Trimethoprim which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Trimipramine.]
[R03DX07, roflumilast, Liothyronine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Liothyronine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Vandetanib.]
[R02AA14, oxyquinoline, Liothyronine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Liothyronine.]
[J05AP02, telaprevir, The excretion of Liothyronine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The excretion of Liothyronine can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Liothyronine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, Liothyronine may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, Liothyronine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[C08DA01, verapamil, The excretion of Liothyronine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, Liothyronine may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The excretion of Liothyronine can be decreased when combined with Vinblastine.]
[L01CA02, vincristine, The excretion of Liothyronine can be decreased when combined with Vincristine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Liothyronine is combined with Warfarin.]
[S01AA13, fusidic acid, The excretion of Liothyronine can be decreased when combined with Fusidic acid.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The excretion of Zidovudine can be decreased when combined with Liothyronine.]
[J05AE02, indinavir, The metabolism of Liothyronine can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Liothyronine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Liothyronine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Crizotinib.]
[A02BC04, rabeprazole, Liothyronine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[L01XX02, asparaginase, The therapeutic efficacy of Liothyronine can be increased when used in combination with Asparaginase Escherichia coli.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Liothyronine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The therapeutic efficacy of Liothyronine can be increased when used in combination with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ruxolitinib.]
[G04BD07, tolterodine, Liothyronine may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, The excretion of Doripenem can be decreased when combined with Liothyronine.]
[C07AB03, atenolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Atenolol.]
[M01CB03, auranofin, Liothyronine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Axitinib.]
[H02AB11, prednylidene, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Prednylidene.]
[B03XA04, peginesatide, Liothyronine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Liothyronine may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Liothyronine may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Liothyronine may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Liothyronine may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A08AA11, lorcaserin, Liothyronine may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, Liothyronine may decrease the excretion rate of Mirabegron which could result in a higher serum level.]
[V03AX03, cobicistat, The excretion of Liothyronine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Liothyronine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L01EA04, bosutinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Bosutinib.]
[L04AA31, teriflunomide, The excretion of Liothyronine can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, Liothyronine may increase the vasoconstricting activities of Octopamine.]
[L01EX05, regorafenib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Regorafenib.]
[D02BA02, octinoxate, Liothyronine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Liothyronine can be increased when combined with Nelfinavir.]
[N04BD02, rasagiline, Liothyronine may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[V09IX04, fluorodeoxyglucose F18, Liothyronine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[L01EX07, cabozantinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Cabozantinib.]
[G04BE03, sildenafil, The excretion of Liothyronine can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Liothyronine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ponatinib.]
[A16AX08, teduglutide, Liothyronine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Liothyronine.]
[A16AX09, glycerol phenylbutyrate, Liothyronine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Liothyronine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Liothyronine.]
[M04AB03, benzbromarone, The excretion of Liothyronine can be decreased when combined with Benzbromarone.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Liothyronine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Liothyronine.]
[J02AX04, caspofungin, The excretion of Liothyronine can be decreased when combined with Caspofungin.]
[L03AA12, ancestim, Liothyronine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N02CC02, naratriptan, Liothyronine may increase the vasoconstricting activities of Naratriptan.]
[C10AC04, colesevelam, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Colesevelam.]
[L04AA18, everolimus, The excretion of Liothyronine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Benzatropine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EC02, dabrafenib, The metabolism of Liothyronine can be decreased when combined with Dabrafenib.]
[R02AX03, benzydamine, Benzydamine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EE01, trametinib, Liothyronine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Liothyronine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[L01EB03, afatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Afatinib.]
[N06AX28, levomilnacipran, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Levomilnacipran.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Liothyronine.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Liothyronine.]
[C02KX04, macitentan, Liothyronine may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[L01EL01, ibrutinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ibrutinib.]
[N06AX26, vortioxetine, Liothyronine may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Liothyronine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[J05AP05, simeprevir, The excretion of Liothyronine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Liothyronine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Liothyronine.]
[C01CA27, droxidopa, Liothyronine may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[C07AB04, acebutolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Liothyronine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Liothyronine may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Liothyronine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Liothyronine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C10AB02, bezafibrate, The excretion of Liothyronine can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Liothyronine.]
[L01ED02, ceritinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ceritinib.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Liothyronine is combined with Acenocoumarol.]
[L01EM01, idelalisib, The excretion of Liothyronine can be decreased when combined with Idelalisib.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Liothyronine.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[V03AE01, polystyrene sulfonate, Tolevamer can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Liothyronine.]
[L01EX09, nintedanib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Nintedanib.]
[S03AA06, gentamicin, Liothyronine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Liothyronine can be decreased when combined with Dasabuvir.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Liothyronine is combined with Dicoumarol.]
[B01AF03, edoxaban, Liothyronine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[L01EX08, lenvatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Lenvatinib.]
[J05AP07, daclatasvir, The excretion of Liothyronine can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, Liothyronine may decrease the excretion rate of Acetaminophen which could result in a higher serum level.]
[L01DC01, bleomycin, Liothyronine may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Liothyronine is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J05AP06, asunaprevir, The excretion of Liothyronine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Eluxadoline can be decreased when combined with Liothyronine.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Liothyronine.]
[M02AA25, aceclofenac, Aceclofenac may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M01AB11, acemetacin, Acemetacin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Liothyronine.]
[B02BC05, adrenalone, Liothyronine may increase the vasoconstricting activities of Adrenalone.]
[V03AB37, idarucizumab, Liothyronine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01EB04, osimertinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Liothyronine.]
[L01EE02, cobimetinib, The excretion of Liothyronine can be decreased when combined with Cobimetinib.]
[L01XG03, ixazomib, Liothyronine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[L01ED03, alectinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Alectinib.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Liothyronine.]
[M04AB05, lesinurad, Liothyronine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N02BA02, aloxiprin, The therapeutic efficacy of Liothyronine can be increased when used in combination with Aloxiprin.]
[N03AX23, brivaracetam, Liothyronine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L01XX52, venetoclax, The excretion of Liothyronine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Liothyronine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Liothyronine.]
[A02AD05, aluminum magnesium silicate, Liothyronine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[N06AA19, amineptin, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Amineptine.]
[C03CA02, bumetanide, The excretion of Bumetanide can be decreased when combined with Liothyronine.]
[N01BB01, bupivacaine, Liothyronine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Bupranolol.]
[N05BE01, buspirone, Liothyronine may decrease the excretion rate of Buspirone which could result in a higher serum level.]
[L01XX27, arsenic trioxide, Liothyronine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Liothyronine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[A07EC04, balsalazide, The therapeutic efficacy of Liothyronine can be increased when used in combination with Balsalazide.]
[R03DA08, bamifylline, Liothyronine may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AH05, naldemedine, Liothyronine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Liothyronine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Pregabalin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N06BC01, caffeine, Liothyronine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Liothyronine.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium carbonate.]
[P01CA02, benznidazole, Liothyronine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium chloride.]
[J05AF06, abacavir, Liothyronine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Liothyronine can be increased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, Liothyronine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Phosphate.]
[L01EX10, midostaurin, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Midostaurin.]
[L01ED04, brigatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Brigatinib.]
[J01MA23, delafloxacin, Liothyronine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Liothyronine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Liothyronine can be decreased when combined with Enasidenib.]
[L01EH02, neratinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Neratinib.]
[C07AB07, bisoprolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Liothyronine can be increased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Bopindolol.]
[V03AB23, acetylcysteine, The excretion of Liothyronine can be decreased when combined with Acetylcysteine.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Liothyronine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[M01AB07, bumadizone, Bumadizone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EL02, acalabrutinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Acalabrutinib.]
[N06AA15, butriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The serum concentration of Acetyldigoxin can be decreased when it is combined with Liothyronine.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be decreased when used in combination with Liothyronine.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Liothyronine.]
[R06AX18, acrivastine, Liothyronine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The excretion of Captopril can be decreased when combined with Liothyronine.]
[C01CX09, angiotensin II, Liothyronine may increase the vasoconstricting activities of Angiotensin II.]
[L02BB05, apalutamide, The excretion of Liothyronine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Liothyronine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium polycarbophil.]
[C07AG02, carvedilol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fostamatinib.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Liothyronine.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD14, ceftibuten, The excretion of Ceftibuten can be decreased when combined with Liothyronine.]
[J01GB14, plazomicin, Liothyronine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Celiprolol.]
[A16AX14, migalastat, Liothyronine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Liothyronine may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[L01EB07, dacomitinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Dacomitinib.]
[S01GX12, cetirizine, Liothyronine may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Liothyronine.]
[D08AE05, chloroxylenol, Liothyronine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[R03DA02, oxtriphylline, Liothyronine may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EX12, larotrectinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Larotrectinib.]
[L01EX13, gilteritinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, Liothyronine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[B01AC23, cilostazol, Liothyronine may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[J01FA09, clarithromycin, The excretion of Liothyronine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Liothyronine may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[L01EN01, erdafitinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Erdafitinib.]
[N05BA09, clobazam, Liothyronine may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[H02AB14, cloprednol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Cloprednol.]
[V03AE07, calcium acetate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The excretion of Liothyronine can be decreased when combined with Candesartan.]
[V03AE02, sevelamer, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Sevelamer.]
[H02AB17, cortivazol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Cortivazol.]
[J01DC04, cefaclor, The excretion of Cefaclor can be decreased when combined with Liothyronine.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01XX66, selinexor, The excretion of Liothyronine can be decreased when combined with Selinexor.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DB04, cefazolin, The excretion of Cefazolin can be decreased when combined with Liothyronine.]
[L02BB06, darolutamide, The excretion of Liothyronine can be decreased when combined with Darolutamide.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EX15, pexidartinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DC07, cefotiam, The excretion of Cefotiam can be decreased when combined with Liothyronine.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, The excretion of Ceftizoxime can be decreased when combined with Liothyronine.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EJ02, fedratinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fedratinib.]
[L01EX14, entrectinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Entrectinib.]
[N07XX11, pitolisant, Liothyronine may decrease the excretion rate of Pitolisant which could result in a higher serum level.]
[N04CX01, istradefylline, The excretion of Liothyronine can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Liothyronine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DB01, cephalexin, The excretion of Cephalexin can be decreased when combined with Liothyronine.]
[J01DB02, cephaloridine, The excretion of Cefaloridine can be decreased when combined with Liothyronine.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[H02AB13, deflazacort, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Deflazacort.]
[G03AC09, desogestrel, The metabolism of Liothyronine can be increased when combined with Desogestrel.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M09AX08, golodirsen, Liothyronine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Liothyronine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01EX18, avapritinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Avapritinib.]
[C10AX15, bempedoic acid, The excretion of Liothyronine can be decreased when combined with Bempedoic acid.]
[J05AB16, remdesivir, The excretion of Liothyronine can be decreased when combined with Remdesivir.]
[J05AE05, amprenavir, The excretion of Liothyronine can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Selumetinib.]
[R02AA03, dichlorobenzyl alcohol, Liothyronine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Liothyronine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[M01AH02, rofecoxib, Rofecoxib may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C08CA16, clevidipine, Liothyronine may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The excretion of Liothyronine can be decreased when combined with Dronedarone.]
[V03AE03, lanthanum carbonate, Lanthanum carbonate can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EH03, tucatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tucatinib.]
[L01EX17, capmatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Capmatinib.]
[D07XB03, fluprednidene, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluprednidene.]
[M01AC04, droxicam, Droxicam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[V08CA05, mangafodipir, Liothyronine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Selpercatinib.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J05AX29, fostemsavir, The excretion of Liothyronine can be decreased when combined with Fostemsavir.]
[P01BA01, chloroquine, Liothyronine may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[L01EX23, pralsetinib, The excretion of Liothyronine can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Chlorotrianisene.]
[N05AA01, chlorpromazine, Liothyronine may decrease the excretion rate of Chlorpromazine which could result in a higher serum level.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Liothyronine.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Liothyronine may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[V04CK02, cholecystokinin, The excretion of Liothyronine can be decreased when combined with Cholecystokinin.]
[N02BA07, ethenzamide, Ethenzamide may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, The therapeutic efficacy of Liothyronine can be increased when used in combination with Choline salicylate.]
[M01AB08, etodolac, Etodolac may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M02AA06, etofenamate, Etofenamate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M01AX25, chondroitin sulfates, Liothyronine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01EX21, tepotinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tepotinib.]
[M01AE05, fenbufen, Fenbufen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N06BA10, fenethylline, Liothyronine may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA19, fenoldopam, Liothyronine may decrease the excretion rate of Fenoldopam which could result in a higher serum level.]
[N06BA08, fenozolone, The risk or severity of adverse effects can be increased when Fenozolone is combined with Liothyronine.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Liothyronine.]
[S02BA08, fluocinolone acetonide, Liothyronine may decrease the excretion rate of Fluocinolone acetonide which could result in a higher serum level.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Liothyronine.]
[N02BG07, flupirtine, Liothyronine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Liothyronine.]
[L01EK03, tivozanib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tivozanib.]
[A02BA01, cimetidine, The excretion of Cimetidine can be decreased when combined with Liothyronine.]
[V08CA04, gadoteridol, Liothyronine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[L01EN03, infigratinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Infigratinib.]
[S03AA07, ciprofloxacin, Liothyronine may decrease the excretion rate of Ciprofloxacin which could result in a higher serum level.]
[L01XA01, cisplatin, Liothyronine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA48, belumosudil, The excretion of Liothyronine can be decreased when combined with Belumosudil.]
[V09AB03, ioflupane I-123, Liothyronine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Liothyronine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Liothyronine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Liothyronine.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Liothyronine.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Clenbuterol is combined with Liothyronine.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium glubionate anhydrous.]
[L01EA06, asciminib, The metabolism of Liothyronine can be decreased when combined with Asciminib.]
[C10AB01, clofibrate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Liothyronine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, Liothyronine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[L01EJ03, pacritinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Clomipramine.]
[N03AE01, clonazepam, Liothyronine may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Liothyronine.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Liothyronine.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA56, deucravacitinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Deucravacitinib.]
[N05AH02, clozapine, Liothyronine may decrease the excretion rate of Clozapine which could result in a higher serum level.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Liothyronine.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Liothyronine.]
[J01GB12, arbekacin, Liothyronine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, Liothyronine may increase the vasoconstricting activities of Cocaine.]
[M01AX13, proquazone, Proquazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M04AC01, colchicine, Liothyronine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Liothyronine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XB01, colistin, Liothyronine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A04AA03, tropisetron, Liothyronine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Liothyronine.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Liothyronine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Liothyronine.]
[J01FA15, telithromycin, The excretion of Liothyronine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The therapeutic efficacy of Liothyronine can be increased when used in combination with Ciclesonide.]
[B01AC10, indobufen, Indobufen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J05AB14, valganciclovir, Liothyronine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Liothyronine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Liothyronine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Liothyronine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Liothyronine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Liothyronine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N02CC05, almotriptan, Liothyronine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01AD03, acyclovir, The excretion of Acyclovir can be decreased when combined with Liothyronine.]
[N05BA10, ketazolam, Liothyronine may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01EA01, imatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Imatinib.]
[N03AX09, lamotrigine, The metabolism of Liothyronine can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Cortisone.]
[N07BC04, lofexidine, Liothyronine may decrease the excretion rate of Lofexidine which could result in a higher serum level.]
[M01AB09, lonazolac, Lonazolac may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M02AA31, loxoprofen, Loxoprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C09AA03, lisinopril, Liothyronine may decrease the excretion rate of Lisinopril which could result in a higher serum level.]
[A06AD01, magnesium carbonate, Liothyronine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[A08AA09, mefenorex, The risk or severity of adverse effects can be increased when Mefenorex is combined with Liothyronine.]
[C07AA14, mepindolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Meprednisone.]
[J01DH02, meropenem, Liothyronine may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[R03CB02, methoxyphenamine, The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Liothyronine.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, Liothyronine may decrease the excretion rate of Melperone which could result in a higher serum level.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Liothyronine.]
[J05AF07, tenofovir disoproxil, The excretion of Tenofovir disoproxil can be decreased when combined with Liothyronine.]
[S01XA18, cyclosporine, The excretion of Liothyronine can be decreased when combined with Cyclosporine.]
[C10AA07, rosuvastatin, The excretion of Rosuvastatin can be decreased when combined with Liothyronine.]
[M02AA02, mofebutazone, Mofebutazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M01AX22, morniflumate, Morniflumate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH05, etoricoxib, Etoricoxib may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01AX04, dacarbazine, Liothyronine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[G03XA01, danazol, The therapeutic efficacy of Liothyronine can be increased when used in combination with Danazol.]
[M03CA01, dantrolene, The therapeutic efficacy of Dantrolene can be increased when used in combination with Liothyronine.]
[M01AX01, nabumetone, Nabumetone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N07BB05, nalmefene, Liothyronine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[C07AB12, nebivolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Liothyronine may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Nefazodone.]
[C01DX16, nicorandil, Liothyronine may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Liothyronine may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[C01CA23, theodrenaline, Liothyronine may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AX05, fondaparinux, Liothyronine may decrease the excretion rate of Fondaparinux which could result in a higher serum level.]
[N06AB10, escitalopram, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.]
[A07EC03, olsalazine, The therapeutic efficacy of Liothyronine can be increased when used in combination with Olsalazine.]
[N06AA01, desipramine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Desipramine.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[V04CH02, indigo carmine, Liothyronine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Liothyronine may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[M01AE12, oxaprozin, Oxaprozin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S03BA01, dexamethasone, The excretion of Dexamethasone can be decreased when combined with Liothyronine.]
[L01EB01, gefitinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Liothyronine.]
[N06AB05, paroxetine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.]
[N07BC06, heroin, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Liothyronine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, Liothyronine may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AC04, permethrin, Liothyronine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Diazepam.]
[N06AA08, dibenzepin, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Dibenzepin.]
[R05DA08, pholcodine, Liothyronine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The excretion of Liothyronine can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A03AA07, dicyclomine, Liothyronine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Liothyronine may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Liothyronine.]
[L01EB02, erlotinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Liothyronine.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Diethylstilbestrol.]
[C08CA03, isradipine, Isradipine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[D07XC04, diflucortolone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Difluocortolone.]
[N02BA11, diflunisal, The therapeutic efficacy of Liothyronine can be increased when used in combination with Diflunisal.]
[C01AA05, digoxin, The serum concentration of Digoxin can be decreased when it is combined with Liothyronine.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Polyestradiol phosphate.]
[L01XX24, pegaspargase, The therapeutic efficacy of Liothyronine can be increased when used in combination with Pegaspargase.]
[N02CA01, dihydroergotamine, Liothyronine may increase the vasoconstricting activities of Dihydroergotamine.]
[N02AA03, hydromorphone, Liothyronine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Liothyronine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Liothyronine can be decreased when combined with Atazanavir.]
[H03BC01, potassium perchlorate, Liothyronine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Liothyronine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[V03AB09, dimercaprol, Liothyronine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Procaterol is combined with Liothyronine.]
[M02AX03, dimethyl sulfoxide, Liothyronine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N06BC02, propentofylline, Liothyronine may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, Propyphenazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M01AB14, proglumetacin, Proglumetacin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Liothyronine.]
[R03DA03, proxyphylline, Liothyronine may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Liothyronine.]
[B01AC07, dipyridamole, The excretion of Liothyronine can be decreased when combined with Dipyridamole.]
[N06AA23, quinupramine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Quinupramine.]
[S01XA23, sirolimus, The excretion of Liothyronine can be decreased when combined with Sirolimus.]
[S01AX06, resorcinol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Resorcinol.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Liothyronine.]
[S02AA12, rifamycin SV, The excretion of Liothyronine can be decreased when combined with Rifamycin.]
[R06AE09, levocetirizine, Liothyronine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Liothyronine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Liothyronine.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Liothyronine may decrease the excretion rate of Tadalafil which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N02BA06, salsalate, Salsalate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Dobutamine is combined with Liothyronine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Dopamine is combined with Liothyronine.]
[N06AA16, dothiepin, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N06AB06, sertraline, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Sertraline.]
[A08AA10, sibutramine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Sibutramine.]
[C10AA01, simvastatin, The excretion of Liothyronine can be decreased when combined with Simvastatin.]
[A12CA02, sodium sulfate, Liothyronine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, Liothyronine may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Liothyronine may decrease the excretion rate of Sumatriptan which could result in a higher serum level.]
[V04CX07, edrophonium, Liothyronine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Talinolol.]
[J01CG02, tazobactam, The excretion of Tazobactam can be decreased when combined with Liothyronine.]
[L01AX03, temozolomide, Liothyronine may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C07AA16, tertatolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Tetryzoline is combined with Liothyronine.]
[N06AX14, tianeptine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Tianeptine.]
[G03CX01, tibolone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tibolone.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N06AG03, toloxatone, Liothyronine may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, Liothyronine may decrease the excretion rate of Atomoxetine which could result in a higher serum level.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of adverse effects can be increased when Tramazoline is combined with Liothyronine.]
[N05CC01, chloral hydrate, Liothyronine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[S01FB02, ephedrine, The risk or severity of adverse effects can be increased when Ephedrine is combined with Liothyronine.]
[N06AX16, venlafaxine, Liothyronine may decrease the excretion rate of Venlafaxine which could result in a higher serum level.]
[S01GA03, xylometazoline, Liothyronine may increase the vasoconstricting activities of Xylometazoline.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Epinephrine is combined with Liothyronine.]
[M01AB04, zomepirac, Zomepirac may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Liothyronine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C02AC02, guanfacine, Liothyronine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02CA02, ergotamine, Liothyronine may increase the vasoconstricting activities of Ergotamine.]
[N03AG01, valproic acid, The excretion of Valproic acid can be decreased when combined with Liothyronine.]
[L03AX05, pidotimod, Liothyronine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The excretion of Liothyronine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Liothyronine may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, The excretion of Liothyronine can be decreased when combined with Pantoprazole.]
[G03CA03, estradiol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Liothyronine can be decreased when used in combination with Conjugated estrogens.]
[J04AK02, ethambutol, Liothyronine may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Liothyronine can be increased when used in combination with Fluticasone furoate.]
[R03BA05, fluticasone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluticasone.]
[C10AA04, fluvastatin, The excretion of Liothyronine can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of adverse effects can be increased when Gepefrine is combined with Liothyronine.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ethinylestradiol.]
[J04AD03, ethionamide, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Ethionamide.]
[C01BD05, ibutilide, Liothyronine may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be increased when used in combination with Liothyronine.]
[M01AC06, meloxicam, Meloxicam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Etilefrine is combined with Liothyronine.]
[N01AX07, etomidate, Liothyronine may decrease the excretion rate of Etomidate which could result in a higher serum level.]
[L04AD02, tacrolimus, The excretion of Liothyronine can be decreased when combined with Tacrolimus.]
[P01AX07, trimetrexate, Liothyronine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Liothyronine may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C10AA03, pravastatin, The excretion of Pravastatin can be decreased when combined with Liothyronine.]
[M01CB01, gold sodium thiomalate, The metabolism of Liothyronine can be decreased when combined with Sodium aurothiomalate.]
[B05AA05, dextran, Liothyronine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Liothyronine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, The excretion of Famotidine can be decreased when combined with Liothyronine.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Liothyronine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Liothyronine.]
[N02AB03, fentanyl, Liothyronine may decrease the excretion rate of Fentanyl which could result in a higher serum level.]
[R03CC02, albuterol, Liothyronine may decrease the excretion rate of Salbutamol which could result in a higher serum level.]
[L01BB06, clofarabine, The excretion of Clofarabine can be decreased when combined with Liothyronine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[G04BD02, flavoxate, Liothyronine may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, Floctafenine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J02AX01, flucytosine, Liothyronine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Liothyronine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N05CD03, flunitrazepam, The metabolism of Liothyronine can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The therapeutic efficacy of Liothyronine can be increased when used in combination with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Melitracen.]
[H02AB03, fluocortolone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluocortolone.]
[L01BC09, floxuridine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Floxuridine.]
[L01BC02, fluorouracil, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluorouracil.]
[N06AB03, fluoxetine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluoxetine.]
[N05CD01, flurazepam, Liothyronine may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The metabolism of Liothyronine can be decreased when combined with Flurbiprofen.]
[L02BB01, flutamide, Liothyronine may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S02AA17, fosfomycin, Liothyronine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L01BC03, tegafur, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Tegafur.]
[J05AE10, darunavir, The excretion of Liothyronine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The protein binding of Liothyronine can be decreased when combined with Furosemide.]
[N05CF04, eszopiclone, Liothyronine may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[S01AD09, ganciclovir, Liothyronine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[C10AB04, gemfibrozil, The metabolism of Liothyronine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Liothyronine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[L01EA02, dasatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Dasatinib.]
[C01CA21, cafedrine, Liothyronine may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Liothyronine.]
[A12AA13, calcium citrate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium levulinate.]
[L01EH01, lapatinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Liothyronine.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Liothyronine.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Liothyronine.]
[N05CM18, dexmedetomidine, Liothyronine may decrease the excretion rate of Dexmedetomidine which could result in a higher serum level.]
[L01EX02, sorafenib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Sorafenib.]
[C07AB09, esmolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Esmolol.]
[M01CB04, aurothioglucose, Liothyronine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Liothyronine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Liothyronine is combined with Fluindione.]
[C09AA09, fosinopril, Liothyronine may decrease the excretion rate of Fosinopril which could result in a higher serum level.]
[S01EX01, guanethidine, Liothyronine may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N05AD01, haloperidol, Liothyronine may decrease the excretion rate of Haloperidol which could result in a higher serum level.]
[N05AH04, quetiapine, Liothyronine may decrease the excretion rate of Quetiapine which could result in a higher serum level.]
[N06BX13, idebenone, Liothyronine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Liothyronine.]
[L01CE02, irinotecan, The excretion of Liothyronine can be decreased when combined with Irinotecan.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Liothyronine.]
[S01XA14, heparin, The therapeutic efficacy of Heparin can be increased when used in combination with Liothyronine.]
[G03DC01, allylestrenol, Liothyronine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The therapeutic efficacy of Liothyronine can be increased when used in combination with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[M02AA26, nimesulide, Nimesulide may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C09AA04, perindopril, Liothyronine may decrease the excretion rate of Perindopril which could result in a higher serum level.]
[C02DB02, hydralazine, Liothyronine may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Liothyronine.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Liothyronine.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Liothyronine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[G04BD06, propiverine, Liothyronine may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[B05AA07, hetastarch, Liothyronine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[R02AX02, ibuprofen, Ibuprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[B05XA08, sodium acetate, Liothyronine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Liothyronine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Imipramine.]
[H01BA04, terlipressin, Liothyronine may increase the vasoconstricting activities of Terlipressin.]
[R01AD07, tixocortol, Liothyronine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[L01CE01, topotecan, Liothyronine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The excretion of Indomethacin can be decreased when combined with Liothyronine.]
[A11HA07, inositol, Liothyronine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Milnacipran.]
[S01XA28, varenicline, Liothyronine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Liothyronine.]
[N05BA12, alprazolam, Liothyronine may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Liothyronine may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Liothyronine.]
[C10AA06, cerivastatin, The excretion of Liothyronine can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Liothyronine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Iprindole.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Liothyronine.]
[J04AC01, isoniazid, Liothyronine may decrease the excretion rate of Isoniazid which could result in a higher serum level.]
[J05AX05, inosine pranobex, Liothyronine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Isoprenaline is combined with Liothyronine.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Liothyronine.]
[C01DA14, isosorbide mononitrate, Liothyronine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Liothyronine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Liothyronine.]
[P02CF01, ivermectin, The excretion of Liothyronine can be decreased when combined with Ivermectin.]
[S01AA24, kanamycin, Liothyronine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, The risk or severity of hypertension and Tachycardia can be increased when Ketamine is combined with Liothyronine.]
[B01AC22, prasugrel, Liothyronine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Liothyronine can be decreased when combined with Ketoconazole.]
[M02AA10, ketoprofen, Ketoprofen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[V03AC03, deferasirox, The metabolism of Liothyronine can be decreased when combined with Deferasirox.]
[D10AX03, azelaic acid, Liothyronine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C07AG01, labetalol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Labetalol.]
[N04BB01, amantadine, Liothyronine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[A06AX03, lubiprostone, Liothyronine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA21, amikacin, Liothyronine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA07, lofepramine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Lofepramine.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium pangamate.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C10AA02, lovastatin, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Lovastatin.]
[H01BA03, lypressin, Liothyronine may increase the vasoconstricting activities of Lypressin.]
[B05XA11, magnesium chloride, Liothyronine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Liothyronine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[L01BA05, pralatrexate, Liothyronine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Liothyronine may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, Liothyronine may decrease the excretion rate of Mecamylamine which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C01AA08, medigoxin, The serum concentration of Metildigoxin can be decreased when it is combined with Liothyronine.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Liothyronine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Liothyronine may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Mephentermine is combined with Liothyronine.]
[N03AB04, mephenytoin, The therapeutic efficacy of Mephenytoin can be increased when used in combination with Liothyronine.]
[N01BB03, mepivacaine, Liothyronine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Liothyronine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX13, paliperidone, Liothyronine may decrease the excretion rate of Paliperidone which could result in a higher serum level.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Metaraminol is combined with Liothyronine.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Liothyronine.]
[N07BC02, methadone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Methadone.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Liothyronine.]
[J05AF05, lamivudine, Liothyronine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Liothyronine may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Liothyronine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Liothyronine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Methoxamine is combined with Liothyronine.]
[D05BA02, methoxsalen, Liothyronine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Liothyronine may decrease the excretion rate of Methyldopa which could result in a higher serum level.]
[V04CG05, methylene blue, Liothyronine may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[R03DA05, aminophylline, Liothyronine may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[G03EK01, methyltestosterone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Methyltestosterone.]
[N02CA04, methysergide, Liothyronine may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Metoclopramide.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Metoprolol.]
[V04CD01, metyrapone, Liothyronine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N02BB03, aminopyrine, Aminophenazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N05CD08, midazolam, Liothyronine may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of adverse effects can be increased when Midodrine is combined with Liothyronine.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Liothyronine.]
[J05AH01, zanamivir, Liothyronine may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The excretion of Liothyronine can be decreased when combined with Valsartan.]
[L01XX23, mitotane, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Liothyronine.]
[L03AC01, aldesleukin, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Aldesleukin.]
[C01BD01, amiodarone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Amitriptyline.]
[A04AA05, palonosetron, Liothyronine may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Liothyronine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[B02BX05, eltrombopag, The metabolism of Liothyronine can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Liothyronine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Pazopanib.]
[L04AA06, mycophenolic acid, Liothyronine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N06AA17, amoxapine, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Amoxapine.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Liothyronine.]
[C07AA12, nadolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Liothyronine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Liothyronine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[S01XA11, nandrolone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Nandrolone phenpropionate.]
[S01GA01, naphazoline, The risk or severity of adverse effects can be increased when Naphazoline is combined with Liothyronine.]
[N06BA01, amphetamine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Liothyronine.]
[M02AA12, naproxen, Naproxen may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Liothyronine.]
[N06AX21, duloxetine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Duloxetine.]
[N04BX01, tolcapone, Liothyronine may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[S03AA01, neomycin, Liothyronine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Liothyronine.]
[B01AC17, tirofiban, Liothyronine may decrease the excretion rate of Tirofiban which could result in a higher serum level.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01AA19, ampicillin, Liothyronine may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Liothyronine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Liothyronine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Desvenlafaxine.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Liothyronine.]
[C01CE01, inamrinone, Liothyronine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The therapeutic efficacy of Liothyronine can be increased when used in combination with Niacin.]
[C08CA04, nicardipine, The excretion of Liothyronine can be decreased when combined with Nicardipine.]
[C08CA05, nifedipine, Liothyronine may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, Niflumic acid may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C08CA07, nisoldipine, Liothyronine may decrease the excretion rate of Nisoldipine which could result in a higher serum level.]
[R07AX01, nitric oxide, Liothyronine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Liothyronine may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, Liothyronine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Liothyronine may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, Liothyronine may decrease the excretion rate of Nitroprusside which could result in a higher serum level.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Norepinephrine is combined with Liothyronine.]
[N06AA10, nortriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of adverse effects can be increased when Nylidrin is combined with Liothyronine.]
[G01AA01, nystatin, The excretion of Liothyronine can be decreased when combined with Nystatin.]
[N06AA05, opipramol, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Opipramol.]
[N02AA02, opium, Liothyronine may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Liothyronine.]
[H01BA05, ornipressin, Liothyronine may increase the vasoconstricting activities of Ornipressin.]
[G04CA02, tamsulosin, Liothyronine may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[C01AC01, ouabain, The excretion of Liothyronine can be decreased when combined with Ouabain.]
[J01CF04, oxacillin, Liothyronine may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[A14AA08, oxandrolone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Oxandrolone.]
[N05BA04, oxazepam, Liothyronine may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[C07AA02, oxprenolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Oxprenolol.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Liothyronine.]
[A14AA05, oxymetholone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Oxymetholone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01AA04, oxytetracycline, The excretion of Oxytetracycline can be decreased when combined with Liothyronine.]
[V04CH30, 4-aminohippuric acid, The excretion of Aminohippuric acid can be decreased when combined with Liothyronine.]
[J04AA01, aminosalicylic acid, The therapeutic efficacy of Liothyronine can be increased when used in combination with Aminosalicylic acid.]
[J04AB30, capreomycin, Liothyronine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[H02AB05, paramethasone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Paramethasone.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[G04BD11, fesoterodine, Liothyronine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Penbutolol.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Liothyronine.]
[J01CE09, penicillin G procaine, Liothyronine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Liothyronine may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Liothyronine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Liothyronine may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB03, perphenazine, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Perphenazine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[N06AF03, phenelzine, Liothyronine may decrease the excretion rate of Phenelzine which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Liothyronine.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Liothyronine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Liothyronine can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Liothyronine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of adverse effects can be increased when Phentermine is combined with Liothyronine.]
[V03AB36, phentolamine, Liothyronine may decrease the excretion rate of Phentolamine which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Phenylephrine is combined with Liothyronine.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Liothyronine.]
[N03AB02, phenytoin, The metabolism of Liothyronine can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, Liothyronine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Liothyronine.]
[B02BA01, vitamin K1, Liothyronine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[C07AA03, pindolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The excretion of Liothyronine can be decreased when combined with Atorvastatin.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Liothyronine.]
[J05AE01, saquinavir, The excretion of Liothyronine can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, The risk or severity of confusion, irritability, and sleep disorders can be increased when Liothyronine is combined with Piracetam.]
[S01BC06, piroxicam, Piroxicam may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Liothyronine.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Liothyronine.]
[J05AE03, ritonavir, The metabolism of Liothyronine can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Liothyronine.]
[B05XA01, potassium chloride, Liothyronine may decrease the excretion rate of Potassium chloride which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Liothyronine.]
[C10AA08, pitavastatin, The excretion of Liothyronine can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Practolol.]
[H02AB07, prednisone, The therapeutic efficacy of Liothyronine can be increased when used in combination with Prednisone.]
[N03AA03, primidone, The metabolism of Liothyronine can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Liothyronine can be decreased when combined with Probenecid.]
[C01BA02, procainamide, Liothyronine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AB05, fenofibrate, Liothyronine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The excretion of Liothyronine can be decreased when combined with Progesterone.]
[R06AD02, promethazine, Liothyronine may decrease the excretion rate of Promethazine which could result in a higher serum level.]
[C01BC03, propafenone, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Propafenone.]
[A03AB05, propantheline, Liothyronine may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Liothyronine.]
[N01AX10, propofol, The metabolism of Liothyronine can be decreased when combined with Propofol.]
[C07AA05, propranolol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Liothyronine may decrease the excretion rate of Rizatriptan which could result in a higher serum level.]
[B01AC09, epoprostenol, Liothyronine may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of Cardiac Arrhythmia can be increased when Liothyronine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Liothyronine.]
[N07XX07, dalfampridine, Liothyronine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Liothyronine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Liothyronine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[C01BA01, quinidine, Liothyronine may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Liothyronine.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Liothyronine.]
[C02AA02, reserpine, The excretion of Liothyronine can be decreased when combined with Reserpine.]
[J05AP01, ribavirin, Liothyronine may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Liothyronine can be increased when combined with Rifampicin.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Ritodrine is combined with Liothyronine.]
[J01FA06, roxithromycin, The excretion of Liothyronine can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may decrease the excretion rate of Liothyronine which could result in a higher serum level.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Liothyronine can be increased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Liothyronine can be increased when used in combination with Salicylic acid.]
[N05CA06, secobarbital, Liothyronine may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[J01GB08, sisomicin, Liothyronine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Liothyronine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Liothyronine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The therapeutic efficacy of Liothyronine can be decreased when used in combination with Sotalol.]
[L01CD04, cabazitaxel, The excretion of Liothyronine can be decreased when combined with Cabazitaxel.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Liothyronine which could result in a lower serum level and potentially a reduction in efficacy.]
